Evista (raloxifene hydrochloride, manufactured by Eli Lilly) has been approved by the FDA to treat the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at risk for invasive breast cancer. Evista is a member of the class of selective estrogen receptor modulator (SERM) drugs and blocks breast estrogen receptors. Evista is currently approved to prevent osteoporosis in postmenopausal women and to treat osteoporosis in postmenopausal women. This approval was based on 3 clinical trials involving ovr 15,000 postmenopausal women comparing Evista with placebo, where Evista was seen to reduce the risk of invasive breast cancer by 44-71%. Serious side effects include blood clots in the legs and lungs and death due to stroke. Source: FDA website. See also Evista website.